Escitalopram ((S)-Citalopram), (S)-+ Citalopram)) is a selective serotonin reuptake inhibitor (SSRI) with a Ki value of 0.89 nM. Escitalopram has approximately 30-fold higher binding affinity than its R(-)-enantiomer and exhibits selectivity over both norepinephrine transporter (NET) and dopamine transporter (DAT).

Escitalopram ((S)-Citalopram), (S)-+ Citalopram)) is a selective serotonin reuptake inhibitor (SSRI) with a Ki value of 0.89 nM. Escitalopram has approximately 30-fold higher binding affinity than its R(-)-enantiomer and exhibits selectivity over both norepinephrine transporter (NET) and dopamine transporter (DAT).

Estramustine(NSC-89201, LEO275) is used to treat hormone-resistant prostate cancer and stabilize microtubule dynamics. It acts as an anti-mitotic and anti-microtubule agent and disrupts microtubule disassembly. It inhibits the binding of MAPs 1 and 2 to taxol-stabilized microtubules, hinders microtubule assembly, and promotes the disassembly of MAP-2-associated microtubules.

Estramustine(NSC-89201, LEO275) is used to treat hormone-resistant prostate cancer and stabilize microtubule dynamics. It acts as an anti-mitotic and anti-microtubule agent and disrupts microtubule disassembly. It inhibits the binding of MAPs 1 and 2 to taxol-stabilized microtubules, hinders microtubule assembly, and promotes the disassembly of MAP-2-associated microtubules.

Estramustine(NSC-89201, LEO275) is used to treat hormone-resistant prostate cancer and stabilize microtubule dynamics. It acts as an anti-mitotic and anti-microtubule agent and disrupts microtubule disassembly. It inhibits the binding of MAPs 1 and 2 to taxol-stabilized microtubules, hinders microtubule assembly, and promotes the disassembly of MAP-2-associated microtubules.

Estramustine(NSC-89201, LEO275) is used to treat hormone-resistant prostate cancer and stabilize microtubule dynamics. It acts as an anti-mitotic and anti-microtubule agent and disrupts microtubule disassembly. It inhibits the binding of MAPs 1 and 2 to taxol-stabilized microtubules, hinders microtubule assembly, and promotes the disassembly of MAP-2-associated microtubules.

Flecainide hydrochloride, an antiarrhythmic drug, is a blocker of hydrophilic sodium channels with a pKa of 9.3. At pH 7.4. It also inhibits the ryanodine receptor (RyR2), reducing spontaneous calcium release from the sarcoplasmic reticulum.

Flecainide hydrochloride, an antiarrhythmic drug, is a blocker of hydrophilic sodium channels with a pKa of 9.3. At pH 7.4. It also inhibits the ryanodine receptor (RyR2), reducing spontaneous calcium release from the sarcoplasmic reticulum.

Flecainide hydrochloride, an antiarrhythmic drug, is a blocker of hydrophilic sodium channels with a pKa of 9.3. At pH 7.4. It also inhibits the ryanodine receptor (RyR2), reducing spontaneous calcium release from the sarcoplasmic reticulum.

Formoterol is a highly selective and potent long-acting beta2-adrenergic agonist that functions by binding to and activating beta2-adrenergic receptors on the smooth muscle cells of the airways. It is used in the treatment of patients with chronic obstructive pulmonary disease (COPD).